WO2012123561A3 - Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer - Google Patents

Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer Download PDF

Info

Publication number
WO2012123561A3
WO2012123561A3 PCT/EP2012/054627 EP2012054627W WO2012123561A3 WO 2012123561 A3 WO2012123561 A3 WO 2012123561A3 EP 2012054627 W EP2012054627 W EP 2012054627W WO 2012123561 A3 WO2012123561 A3 WO 2012123561A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
age
agent
treatment
disorders
Prior art date
Application number
PCT/EP2012/054627
Other languages
English (en)
French (fr)
Other versions
WO2012123561A2 (de
Inventor
Florian Lang
Jakob VOELKL
Cai TANG
Leticia QUINTANILLA-MARTINEZ DE FEND
Original Assignee
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum filed Critical Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
Publication of WO2012123561A2 publication Critical patent/WO2012123561A2/de
Publication of WO2012123561A3 publication Critical patent/WO2012123561A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Agens zur Prophylaxe und/oder Behandlung einer altersassoziierten Krankheit und/oder Störung sowie zur Verlängerung der Lebensdauer eines Lebewesens und damit im Zusammenhang stehende Verfahren.
PCT/EP2012/054627 2011-03-17 2012-03-16 Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer WO2012123561A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011015142A DE102011015142A1 (de) 2011-03-17 2011-03-17 Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer
DE102011015142.7 2011-03-17

Publications (2)

Publication Number Publication Date
WO2012123561A2 WO2012123561A2 (de) 2012-09-20
WO2012123561A3 true WO2012123561A3 (de) 2013-01-03

Family

ID=45876727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/054627 WO2012123561A2 (de) 2011-03-17 2012-03-16 Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer

Country Status (2)

Country Link
DE (1) DE102011015142A1 (de)
WO (1) WO2012123561A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014202744A1 (en) 2013-06-21 2014-12-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning
GB201708456D0 (en) * 2017-05-26 2017-07-12 Medical Res Council Senolytic compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162759A1 (en) * 2000-07-27 2003-08-28 Ricardo Rocha Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US20030191100A1 (en) * 1999-11-09 2003-10-09 Pharmacia Corporation, Corporate Patent Department Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
WO2004017906A2 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
US20040087563A1 (en) * 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20080221084A1 (en) * 2006-10-30 2008-09-11 Otsuka Pharmaceutical Co., Ltd. Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367417A1 (en) * 2001-07-19 2005-02-21 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
WO2005039637A2 (en) * 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
JP4783887B2 (ja) * 2005-02-17 2011-09-28 国立大学法人大阪大学 心筋組織の障害を抑制するための医薬組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191100A1 (en) * 1999-11-09 2003-10-09 Pharmacia Corporation, Corporate Patent Department Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030162759A1 (en) * 2000-07-27 2003-08-28 Ricardo Rocha Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2004017906A2 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
US20040087563A1 (en) * 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20080221084A1 (en) * 2006-10-30 2008-09-11 Otsuka Pharmaceutical Co., Ltd. Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERTRAM PITT ET AL: "Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.", JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM : JRAAS, vol. 4, no. 3, 1 January 2003 (2003-01-01), pages 164, XP055028546, ISSN: 1470-3203, DOI: 10.3317/jraas.2003.025 *
BUTLER J V ET AL: "Spironolactone therapy in older patients: The impact of renal dysfunction", ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol. 35, no. 1, July 2002 (2002-07-01), pages 45 - 49, XP055028422, ISSN: 0167-4943 *
KHACHATURIAN ARA S ET AL: "Antihypertensive medication use and incident Alzheimer disease - The Cache County Study", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 63, no. 5, 1 May 2006 (2006-05-01), pages 686 - 692, XP002564531, ISSN: 0003-9942, [retrieved on 20060313], DOI: 10.1001/ARCHNEUR.63.5.NOC60013 *
LOUISE A. BURTON ET AL: "Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?", CLINICAL ENDOCRINOLOGY, vol. 75, no. 6, 9 November 2011 (2011-11-09), pages 725 - 729, XP055028543, ISSN: 0300-0664, DOI: 10.1111/j.1365-2265.2011.04148.x *
YAGI SHUSUKE ET AL: "High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension.", HYPERTENSION RESEARCH : OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF HYPERTENSION JAN 2011 LNKD- PUBMED:20861841, vol. 34, no. 1, January 2011 (2011-01-01), pages 74 - 78, XP008152357, ISSN: 1348-4214 *
YASAR, S.; ZHOU, J.; VARADHAN, R.; CARLSON, M. C.: "The Use of Angiotensin-converting Enzyme Inhibitors and Diuretics Is Associated With a Reduced Incidence of Impairment on Cognition in Elderly Women", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 84, 19 March 2008 (2008-03-19), pages 119 - 126, XP008152265 *

Also Published As

Publication number Publication date
DE102011015142A1 (de) 2012-09-20
WO2012123561A2 (de) 2012-09-20

Similar Documents

Publication Publication Date Title
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
WO2012125408A8 (en) Pegylated apelin and uses thereof
WO2015001504A3 (en) Antibody formulations and methods
UA114090C2 (uk) Сполуки, що інгібують металоферменти
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2014036219A3 (en) Methods and compositions for treatment of a genetic condition
EP2670478A4 (de) Vorrichtungen, systeme und verfahren zur gezielten behandlung von bewegungsleiden
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EP2967049A4 (de) Verfahren, verbindungen und zusammensetzungen zur behandlung von angiotensin-bedingten erkrankungen
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
EP3060569B8 (de) Di-isopropyl-phosphinoyl-alkan (dapa)-verbindungen als topisches mittel zur behandlung von sensorischen beschwerden
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
BR112013031117A2 (pt) scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TN2016000107A1 (en) Substituted phenylalanine derivatives
HK1216641A1 (zh) 用於治療σ受體相關疾病和病症的 -三唑- -胺
WO2012058529A3 (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710209

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12710209

Country of ref document: EP

Kind code of ref document: A2